FDA Power v. State Laws: Compounders Want Clarity On Office Use
This article was originally published in The Pink Sheet Daily
FDA says traditional compounding pharmacies cannot produce office stock, but some states specifically allow the practice, and the International Academy of Compounding Pharmacists wants help from Congress.
You may also be interested in...
Guidance on compounding commercially available drugs states that prescribers can order them as long as there's a clinical difference for the patient – a standard that likely helps Daraprim but not Lucentis.
The biotech took aim at ophthalmic rival Regeneron with a panel of physicians who pointed out the short-term nature of and side-effects associated with anti-VEGFs. It also emphasized that doctors want several treatments with distinct mechanisms of action, rather than the co-formulations that Regeneron plans.
After the House and Senate question whether FDA needs more authority to regulate compounders like the New England Compounding Center, Sen. Lamar Alexander suggests clearly designating who has jurisdiction may be the answer.